Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis : a propensity-score matched longitudinal cohort study
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVE: Statins are reported to have a potential benefit on progression of OA and on disease activity in RA, but existing evidence is conflicting. Our objective was to examine whether statins associate with reduction in the risk for joint replacement due to OA and RA.
METHODS: This was a propensity score-matched cohort study. Electronic health records from the UK Clinical Practice Research Datalink were used. We selected people prescribed statins and people never prescribed statins. Each statin user was matched to a non-user by age, gender, practice and propensity score for statin prescription. The main outcome measures were knee or hip joint replacement overall, and specifically because of OA or RA. The association between statins and risk of joint replacement was assessed using Cox proportional hazard regression. Statin exposure was categorized according to the potency of reducing low-density lipoprotein as low (21-28%), medium (32-38%) or high (42-55%) intensity.
RESULTS: A total of 178 467 statin users were matched with 178 467 non-users by age, gender, practice and propensity score. Overall, statin was not associated with reduced risk of knee or hip replacement (hazard ratio 0.99, 95% CI: 0.97, 1.03), unless prescribed at high strength (0.86, 0.75-0.98). The reduced risk was only observed for joint replacement due to RA (0.77, 0.63-0.94) but not OA (0.97, 0.94-1.01).
CONCLUSION: Statins at high intensity may reduce the risk of hip or knee replacement. This effect may be RA specific. Further studies to investigate mechanisms of risk reduction and the impact in people with RA are warranted.
| Errataetall: |
ErratumIn: Rheumatology (Oxford). 2020 Oct 1;59(10):3120. - PMID 32556271 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 59(2020), 10 vom: 01. Okt., Seite 2898-2907 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarmanova, Aliya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cohort study |
|---|
| Anmerkungen: |
Date Completed 22.01.2021 Date Revised 22.01.2021 published: Print ErratumIn: Rheumatology (Oxford). 2020 Oct 1;59(10):3120. - PMID 32556271 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keaa044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306899698 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306899698 | ||
| 003 | DE-627 | ||
| 005 | 20231225124402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keaa044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306899698 | ||
| 035 | |a (NLM)32097491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarmanova, Aliya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis |b a propensity-score matched longitudinal cohort study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 22.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Rheumatology (Oxford). 2020 Oct 1;59(10):3120. - PMID 32556271 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: Statins are reported to have a potential benefit on progression of OA and on disease activity in RA, but existing evidence is conflicting. Our objective was to examine whether statins associate with reduction in the risk for joint replacement due to OA and RA | ||
| 520 | |a METHODS: This was a propensity score-matched cohort study. Electronic health records from the UK Clinical Practice Research Datalink were used. We selected people prescribed statins and people never prescribed statins. Each statin user was matched to a non-user by age, gender, practice and propensity score for statin prescription. The main outcome measures were knee or hip joint replacement overall, and specifically because of OA or RA. The association between statins and risk of joint replacement was assessed using Cox proportional hazard regression. Statin exposure was categorized according to the potency of reducing low-density lipoprotein as low (21-28%), medium (32-38%) or high (42-55%) intensity | ||
| 520 | |a RESULTS: A total of 178 467 statin users were matched with 178 467 non-users by age, gender, practice and propensity score. Overall, statin was not associated with reduced risk of knee or hip replacement (hazard ratio 0.99, 95% CI: 0.97, 1.03), unless prescribed at high strength (0.86, 0.75-0.98). The reduced risk was only observed for joint replacement due to RA (0.77, 0.63-0.94) but not OA (0.97, 0.94-1.01) | ||
| 520 | |a CONCLUSION: Statins at high intensity may reduce the risk of hip or knee replacement. This effect may be RA specific. Further studies to investigate mechanisms of risk reduction and the impact in people with RA are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a TJR | |
| 650 | 4 | |a TKR | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a joint replacement | |
| 650 | 4 | |a osteoarthritis | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a statins | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Lipoproteins, LDL |2 NLM | |
| 700 | 1 | |a Doherty, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Changfu |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Abhishek, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Mallen, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yilun |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Guanghua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Weiya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 59(2020), 10 vom: 01. Okt., Seite 2898-2907 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:2898-2907 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keaa044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2020 |e 10 |b 01 |c 10 |h 2898-2907 | ||